Clinical observation of microwave ablation combined with chemotherapy and PD-1 inhibitor for non-small cell lung cancer.

Corresponding author: Luo bingqing, lbqlc@aliyun.com

DOI: 10.12201/bmr.202504.00054

•  

  Abstract: Objective：An exploration and analysis of the clinical efficacy and safety of microwave ablation (MWA) combined with chemotherapy and PD-1 inhibitor for non-small cell lung cancer (NSCLC). Methods：The data of patients with NSCLC who were not suitable for radical surgery or radiotherapy and were histologically confirmed in the Second Affiliated Hospital of Xiamen Medical College from May 2021 to May 2022 were retrospectively collected．The patients receive chemotherapy plus PD-1 inhibitor with or without MWA were included. The include patients were divided into combined group (with MWA) and control group (without MWA) . The overall effective rates, DCR, PFS, and complication rates of the two groups were compared. Results: A total of 73 cases were included. The overall effective rate in the combination therapy group was 72.50%, and the DCR was 95.00%. In the control group, the overall effective rate was 54.54%, and the DCR was 81.81%. There was no statistically significant difference between the two groups in terms of the overall effective rates and DCR(p=0.111and p=0.073, respectively).The PFS of the combined treatment group was 14.97 months, significantly longer than the 9.87 months in the control group(p﹤0.001) .Forty patients who underwent microwave ablation did not experience any severe adverse reactions. Among the 73 patients who received chemotherapy combined with PD-1 inhibitor treatment, the adverse reactions were mainly Grade 1 to Grade 2, with two patients experiencing Grade 3 adverse reactions. Conclusion: MWA combined with chemotherapy plus PD-1 inhibitor can prolong the PFS of patients with NSCLC and has good safety.

  Key words: Microwave ablation; Non-small cell cancer; PD-1 inhibitor; Progression-free survival

  Submit time: 17 April 2025

  Copyright: The copyright holder for this preprint is the author/funder, who has granted biomedRxiv a license to display the preprint in perpetuity.
• html

• 图表

• Clinical research progress of PD-1/PD-L1 inhibitor induction therapy in unresectable stage III non-small-cell lung cancer. 2025. doi: 10.12201/bmr.202501.00025

  Wang Yaoqiang, Wang Haohao, Luo Changjiang. The role of HMGB1 in the progression and therapy of Gastric Cancer. 2024. doi: 10.12201/bmr.202412.00009

  Li Ying, Wang Xiaofei, Lu Shengwei, Dong Danni, Zhang Jingfeng, Zheng Jianjun. CT Findings and Clinical Features of checkpoint Inhibitor-related pneumonitis. 2024. doi: 10.12201/bmr.202407.00008

  Shirong Wang, Yalong Dang. The intraocular pressure lowering effects of ROCK inhibitor: the current concepts and perspectives. 2022. doi: 10.12201/bmr.202210.00014

  QIAN Yun. Adverse events associated with immune checkpoint inhibitors: clinical manifestations and mechanisms. 2025. doi: 10.12201/bmr.202502.00010

  Zhang zhenwen. Effects of SGLT2 inhibitors on the metabolic syndrome and its components. 2025. doi: 10.12201/bmr.202503.00002

  Yuan Heqing, Shao Xiying. . 2025. doi: 10.12201/bmr.202504.00058

  liushunlin. The expression of CPNE1 and ZWILCH in the progression of lung adenocarcinoma and their correlation with prognosis. 2024. doi: 10.12201/bmr.202406.00030

  Yao Genwu, Wang Yanwei, Guo Jinyi, Li Lulu, Dang Wenbo, Song Ailin. Advances in single-cell sequencing in the breast cancer. 2024. doi: 10.12201/bmr.202407.00053

  XUJIE, ZHAOYUNZHEN. Observation on the clinical efficacy of digital templating combined with limited incision in the treatment of ankle fractures. 2025. doi: 10.12201/bmr.202501.00083

• ID	Submit time	Number	Download
  1	2025-03-01	bmr.202504.00054V1	Download

• Public  Anonymous  To author only Submit Comments